Q3 2021 Revance Therapeutics Inc Earnings Call Transcript
Welcome to Revance Therapeutics Third Quarter 2021 Financial Results and Corporate Update Conference Call. (Operator Instructions) As a reminder, this call is being recorded today, 9th of November 2021.
I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations and ESG of Revance. Please go ahead.
Thank you, Laurie. Joining us on the call today from Revance, our Chief Executive Officer, Mark Foley; President, Dustin Sjuts; Chief Financial Officer, Toby Schilke; and Senior Vice President of Clinical Development, Roman Rubio.
During this conference call, management will make forward-looking statements, including statements related to the potential approval and timing of approval of DaxibotulinumtoxinA for Injection in glabellar lines and therapeutic indications; our ability to remediate deficiencies identified by the FDA regarding our BLA; a Type A meeting with the FDA; financial performance, revenue and processing volume run rate; financial
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |